)
Product Pipeline
Focused on Innovation
CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Haematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Core Capabilities
as demonstrated in our product pipeline
Research / Pre-Clinical
Clinical Development
Registration / Post-Registration
CSL888 Haptoglobin (SAH)
Plasma-derived Haptoglobin 1-1 for treatment of patients with aneurysmal Subarachnoid Hemorrhage (aSAH).
CSL510 Modified Fibrinogen
Improved liquid formulation.
CSL040 (Novel Complement Inhibitor)
A recombinant glycoprotein which inhibits the classical, lectin and alternative Complement pathways for the potential treatment of acute indications involving Complement‐mediated tissue damage and inflammation.
SA-mRNA Influenza Vaccine
Self-amplifying mRNA, has the potential to revolutionise influenza protection by using the body’s own cells to create the antigen, rather than injecting the antigen, which is the method used today. cell-free vaccine for the protection against the influenza virus.
LASN01 Anti-IL-11R
Monoclonal antibody targeting IL-11R for development in the areas of fibrosis and oncology.
Licensed to Lassen Therapeutics.
P. Gingivalis (Periodontal Disease)
Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis.
Licensed to Denteric.
Discovery Projects
Discovery projects aiming to grow CSL’s R&D pipeline in our five Therapeutic Areas.
CSL324 Anti-G-CSFR mAb (HS)
Recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor for the potential treatment of Hidradenitis Suppurativa.
CSL730 rFc Multimer*
Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases.
*Developed in collaboration with Momenta Pharmaceuticals.
HIZENTRA® (SSc)
HIZENTRA®, 20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).
HIZENTRA® (DM)
HIZENTRA®, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
HAEGARDA® Japan
Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.
Garadacimab Anti-FXIIa mAb (HAE)
Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.
CSL889 Hemopexin (SCD)
Plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease (SCD).
CSL200 CAL-H (SCD)
Human γ-Globin Gene Therapy for the potential treatment of Severe Sickle Cell Disease (SCD).
CSL630 pdFVIII Ruide
Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).
EtranaDez (AMT-061; Etranacogene dezaparvovec)*
CSL has entered an agreement with uniQure to acquire exclusive global licence rights to an adeno-associated virus (AAV) gene therapy for the potential treatment of haemophilia B.
*Transaction with uniQure is subject to customary regulatory clearances before closing.
KCENTRA® 4F-PCC (Trauma)
A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.
CSL787 Nebulised Ig
Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease.
CSL311 Anti-Beta Common mAb
Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases.
Garadacimab Anti-FXIIa mAb (ILD/IPF)
A humanised anti-FXIIa monoclonal antibody for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD).
CSL346 Anti-VEGFB mAb (DKD)
Humanised monoclonal antibody targeting VEGF-B for the potential treatment of diabetic kidney disease (DKD).
CSL112 ApoA-1 (ACS)
Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with Acute Coronary Syndrome (ACS).
Clazakizumab Anti-IL-6 mAb (AMR)
Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.
CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*
Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)
Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
Adjuvanted Cell Culture Influenza Vaccine (aQIVc)
MF59® adjuvant plus FLUCELVAX® antigen.
Garadacimab Anti-FXIIa mAb (ARDS)
Humanised anti-FXIIa monoclonal antibody for the potential treatment of acute respiratory distress syndrome (ARDS).
COVID-19 Hyperimmune Therapy*
CSL, with Takeda, led the creation of the unprecedented CoVIg-19 Plasma Alliance to accelerate the development of a plasma-derived hyperimmune globulin therapy (CoVIg-19) for the potential treatment of individuals with serious complications of COVID-19.
*Partnered Program
CSL334/ASLAN004 Anti-IL-13R mAb (AD)
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis and asthma.
Licensed to ASLAN Pharmaceuticals.
Mavrilimumab Anti-GM-CSFR mAb
Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases.
Licensed to Kiniksa Pharmaceuticals.
PRIVIGEN® PID Japan
PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of primary immunodeficiency disease (PID).
IDELVION® rFIX-FP (Haem B)
Novel, long-acting recombinant factor IX product for the treatment of haemophilia B.
AFSTYLA® rFVIII (Haem A)
Novel, recombinant factor VIII product for the treatment of adults and children with haemophilia A.
ZEMAIRA®/RESPREEZA® Alpha1-Proteinase Inhibitor
Alpha1-Proteinase Inhibitor (Human) for treatment of Alpha- 1 Antitrypsin (AAT) Deficiency.
AFLURIA® QUAD Egg-based Influenza Vaccine
Seasonal egg-based split viron quadrivalent influenza vaccine registered in the US and Australia for use in children 6 months of age and older.
FLUCELVAX® Quadrivalent Cell-based Influenza Vaccine
Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.
FLUAD® Quadrivalent Adjuvanted Influenza Vaccine
Seasonal, egg-based quadrivalent vaccine, combined with Seqirus' proprietary adjuvant, MF59®, to protect against four different strains of influenza.
AUDENZTM Adjuvanted Monovalent Influenza A (H5N1) Vaccine
Pre-pandemic, cell-based vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.